Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.41 |
| ▸ | CA2 | P00918 | 11/20 | 0.41 |
| ▸ | CA12 | O43570 | 10/20 | 0.41 |
| ▸ | CA9 | Q16790 | 10/20 | 0.41 |
| ▸ | CA4 | P22748 | 7/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1826592 | 0.93 | CA1 (0.41) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2191169 | 0.90 | CA12 (0.39) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1823595 | 0.89 | CA1 (0.43) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2189158 | 0.88 | CA12 (0.37) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1819380 | 0.88 | CA1 (0.37) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1818865 | 0.88 | CA1 (0.42) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2191604 | 0.86 | CA1 (0.48) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2195056 | 0.83 | CA1 (0.51) | CA1CA2CA12CA9CA4 | |
| SCHEMBL2192024 | 0.83 | CA1 (0.36) | CA1CA2CA12CA9CA4 | |
| SCHEMBL1820482 | 0.83 | CA1 (0.45) | CA1CA2CA12CA9PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461134-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461134-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110172187-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172187-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172187-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | CA1 4452/4885CA2 1155/4885CA12 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.